February 4, 2012
| Bio-IT World > Zero Chances to Go Wrong


Zero Chances to Go Wrong


INside the Box - Bill van Etten 

April 16, 2004 | Although the line between "bio" and "IT" has become fuzzy, these two groups still have vastly different perspectives. IT seeks to provide a guaranteed level of service and cautious transition from the status quo. Scientists have no use for the status quo and require rapid change.

So why can't we have reliable IT services under conditions of rapid change? The answer is largely because our hardware and software have no inherent "awareness" of other devices and services on the network, and require considerable manual effort to configure and maintain. Zeroconf, an open protocol embraced and branded as "Rendezvous" by Apple Computer, promises to solve this problem.

Zeroconf is an Internet Engineering Task Force (IETF) working group chartered to enable the automatic configuration and discovery of computers, devices, and services on IP networks. It seeks to automate four fundamental tasks:

  • IP address assignment (without a DHCP server)
  • Multicast address allocation (without a MADCAP server)
  • Host name to IP address translation (without a DNS server)
  • Network service registration and discovery

All these tasks would be accomplished automatically, without user intervention and without IT support. Equally important to application developers, the open-source and cross-platform programming model permits consistent coding to LANs and WANs on Windows, Mac, and other Unix platforms. So what does that mean to me, you ask?

It means when you turn on your computer in the absence of a managed network and IT support, you automatically join the local network and can discover and use any network devices available to you.

More interesting cases involve the auto-discovery and use of network services and applications. Apple uses this method for the auto-discovery of commonly shared devices (computers, printers, faxes, and file servers), and for less commonly shared services such as the automatic clustering of many computers into a "single computer" for large BLAST jobs.

Here's how it works.

IP address assignment. Zeroconf enables computers (or any other network devices) to automatically assign themselves a unique "link-local" IP address within the reserved 169.254.1.0 to 169.254.254.255 range in the instance that routable addresses have not been provided through normal means.

Multicast address allocation. Zeroconf enables multicast-based applications to automatically allocate themselves a unique multicast address within the reserved range of 239.255.1.0 to 239.255.254.255, and manages their friendly persistence over time.

Name/address translation. When you browse www.bio-itworld.com, a hierarchical chain of DNS servers is consulted until one returns the DNS record pointing the fully qualified domain name "bio-itworld.com" to the IP address 64.28.79.92, which at some point had to be entered by an IT person into a root DNS server. Zeroconf uses Multicast DNS (mDNS) to do this and resolves names in the ".local." domain. Say you need to talk to "Bob." Unicast DNS is like asking your boss, who might ask his or her boss, and so on up to the CEO if necessary, until someone puts you in contact with Bob. Multicast DNS is like announcing over the public address system, "Could Bob meet me in the lobby, please?"

Service discovery. Zeroconf again uses mDNS broadcast system, but instead of looking for devices, it seeks capabilities. It's like announcing, "Anyone know how to ... ?" and waiting for a response. Zeroconf leverages the seldom-utilized SRV record within the DNS protocol to register/discover this information in the form service.protocol.domain. A client word-processing application would query the network for available LPR printers with "_lpr._tcp.local." and the printer would respond with its name, IP address, and perhaps its capabilities.

Apple's Xgrid software enables Zeroconf but runs only on the Mac. Therefore, as a prize for finishing this month's column, The BioTeam offers its Zeroconf-enabled Sun Grid-Engine at www.bioteam.net/zeroconf.

Bill Van Etten is a consultant for The BioTeam and can be reached at bill@bioteam.net. 




ILLUSTRATION BY MARK STEPHEN



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .